Cited by 309Tissue Engineering and Regenerative MedicineLiver physiology and pathologyMesenchymal stem cell research

Cell and tissue engineering for liver disease

Open access
Bhatia, Sangeeta N., Underhill, Gregory H., Zaret, Kenneth S., Fox, Ira J.·2014·Science Translational Medicine

Abstract

Advances in cell and tissue engineering are moving cell-based therapies for treating liver disease and liver failure closer to the clinic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3005975

Cites

315 of 315 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • iPSC-derived hepatocyte-like cells are still in nascent stages of development and show characteristics similar to fetal hepatocytes.

    “These iPSC-derived hepatocyte-like cells are still in nascent stages of development and show characteristics similar to fetal hepatocytes [76].”

    From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [76]

  • For decades, expandable HHs have been a bottleneck for their applications for research purposes and clinical therapies.

    “For decades, expandable HHs have been a bottleneck for their applications for research purposes and clinical therapies (Bhatia et al., 2014; Michalopoulos, 2014; Mitaka, 1998; Runge et al., 2000”
  • The use of hepatocyte transplantation is hampered by the limited availability of donor hepatocytes and the inability to expand primary HHs in vitro.

    “However, the actual use of hepatocyte transplantation has been hampered by the limited availability of donor hepatocytes and the inability to expand primary HHs (PHHs) in vitro.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. [32]Fox IJ Chowdhury JR Kaufman SS Goertzen TC Chowdhury NR Warkentin PI Dorko K Sauter BV Strom SC Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation N Engl J Med 338 1422 1426 1998 9580649
  2. [39]Michalopoulos GK DeFrances MC Liver Regeneration Science 276 60 66 1997 9082986
  3. [227]Soto-Gutierrez A Kobayashi N Rivas-Carrillo JD Navarro-Alvarez N Zhao D Okitsu T Noguchi H Basma H Tabata Y Chen Y Tanaka K Narushima M Miki A Ueda T Jun HS Yoon JW Lebkowski J Tanaka N Fox IJ Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes Nature Biotechnology 24 1412 1419 2006 17086173
  4. [257]Strom SC Chowdhury JR Fox IJ Hepatocyte transplantation for the treatment of human disease Semin Liver Dis 19 39 48 1999 10349682

Cited by

Sorted by citations

Authors
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of Illinois Urbana-Champaign (US)
  • University of Pennsylvania (US)
  • University of Pittsburgh (US)
Corresponding author
Bhatia, Sangeeta N.
Venue
Science Translational Medicine
Published
2014-07-16
Volume
6
Issue
245
Pages
245sr2-245sr2
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2109789900
Cited by
309
References
315
Citations by year
2026: 11 · 2025: 15 · 2024: 20 · 2023: 15 · 2022: 24 · 2021: 41 · 2020: 40 · 2019: 32 · 2018: 26 · 2017: 31 · 2016: 34 · 2015: 15 · 2014: 3 · 2013: 1 · 2012: 1
FWCI
5.22
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Institute of General Medical Sciences (R01GM036477, R37GM36477, R37GM036477)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK099320, P01DK096990, R01DK48794, R01DK085713, R01DK85713, R01DK048794)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB008396, UH2EB017103, UH3EB017103)
Topics
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
Keywords
liver disease, liver failure, cell therapy, tissue engineering, stem cells, cellular reprogramming, clinical translation, liver regeneration
MeSH terms
Animals, Disease Models, Animal, Humans, Liver, Liver Diseases, Tissue Engineering, Translational Research, Biomedical, Cell Engineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review